Table 1.
Demographic and clinical characteristics of the 17 patients with cutaneous manifestations of lupus erythematosus treated with B-cell depletion therapy at University College London Hospital
| Patient (no./sex/age, y./ethnicity)a | Type of cutaneous manifestationsb | Extra-cutaneous ACR criteria | Disease duration (years) | Previous therapyc | Date of BCDT | BILAG before, 6 mo. After BCDT | Relapse (months after last BCDT) | Follow-up (months) | Maintenance therapyc | Complications |
|---|---|---|---|---|---|---|---|---|---|---|
| 1/M/43/W | SLE (ACLE: malar and disseminated rash) | Lymphopaenia, dsDNA | 10 | HCQ, Pred, Aza, MTX | 09/08; 01/09 | A → A A → C | 3 20 | 36 | HCQ, Pred 5 mg, topical steroids | Urticaria during second cycle of RTX |
| 2/F/50/W | SLE (CCLE: LP) | Pleurisy | 11 | HCQ, Pred, MMF | 08/08; 07/09; 04/11 | B → B B → C B → C | 6 9 11 | 36 | HCQ, Pred 7.5 mg | None |
| 3/F/47/W | SLE (ACLE: generalized rash) | Arthritis | 13 | HCQ, Pred, Aza, MMF, CPM | 04/09 | A → D | 18 | 30 | HCQ, Pred 5 mg | Urticaria and angioedema at second infusion |
| 4/F/57/W | SLE (urticarial vasculitis) | Arthritis | 13 | HCQ, Pred, Aza, MTX | 07/09; 06/11 | A → A A → A | n.a. n.a. | 28 | MMF, HCQ, Pred 5–30 mg | None |
| 5/F/40/AC | SLE (annular SCLE) | Epilepsy | 15 | HCQ, Pred, MTX, MMF | 01/07; 05/11 | A → B A → B | n.a. n.a. | 60 | HCQ, MMF, Pred 10 mg | None |
| 6/F/33/AC | SLE (CCLE: DLE) | Arthritis, Pleurisy,dsDNA | 2 | HCQ, Pred, Aza | 03/10 | A → C | 12 | 21 | HCQ, Aza | None |
| 7/F/46/AC | SLE (ACLE: malar and disseminated rash) | Arthritis, pleurisy, dsDNA | 23 | HCQ, Pred | 05/08; 09/09 | A → D A → D | 15 None | 46 | Pred 5 mg | None |
| 8/F/24/A | SLE (vasculitis) | Arthritis, dsDNA | 9 | HCQ, Pred | 04/08; 09/08 | B → C B → D | 6 None | 37 | HCQ, Pred 5 mg | None |
| 9/F/47/AC | SLE (CCLE: DLE) | Arthritis, pleurisy, epilepsy, dsDNA | 3 | HCQ, Pred, Aza | 12/08; 10/09 | B → B B → C | 4 24 | 25 | HCQ, Pred 10 | None |
| 10/F/48/AC | SLE (CCLE: DLE) | Nephritis, dsDNA | 1 | HCQ, Pred | 10/08 | B → D | None | 25 | HCQ | None |
| 11/F/25/A | SLE (vasculitis) | Arthritis, dsDNA | 16 | HCQ, Pred | 04/10 | B → D | 22 | 24 | HCQ, Pred 3 mg | None |
| 12/F/33/AC | SLE (CCLE: DLE and LP) | Arthritis | 4 | HCQ, Pred | 09/11 | B → B | 6 | 5 | None | None |
| 13/F/23/AC | SLE (CCLE: DLE) | Arthritis | 14 | HCQ, Pred, Aza | 01/10; 09/10 | B → B B → D | 5 16 | 26 | HCQ, Pred 5 mg | None |
| 14/F/23/AC | SLE (CCLE: DLE) | Arthritis, dsDNA | 13 | HCQ, Pred, MTX | 04/09 | A → D | None | 25 | HCQ, Pred 5 mg | None |
| 15/F/74/W | Annular SCLE | None | 3 | Pred, Aza, MTX | 07/06; 07/08 | n.a. | 23 24 | 47 | MTX, Pred 5 mg | None |
| 16/F/65/W | Annular SCLE | None | 7 | Pred, MMF | 03/10 | n.a. | 9 | 20 | Pred 7.5 mg | Recurrent infections |
| 17/F/54/W | DLE + RA | None | 30 | HCQ, Pred, MTX, thalidomide | 07/10 | n.a. | n.a. | 18 | HCQ, Pred 5 mg, MTX | None |
F: female; M: male; W: white, AC: Afro-Caribbean; A: Asian;
bSLE: systemic lupus erythematosus; ACLE: acute cutaneous lupus; CCLE: chronic cutaneous lupus; SCLE: subacute-cutaneous lupus; DLE: discoid lupus erythematosus; LP: lupus erythematosus profundus: RA: rheumatoid arthritis.
HCQ: hydroxychloroquine (administered for ≥6 months); Pred: oral prednisolone; Aza: azathioprine (≥1.5 mg/kg/d); MTX: methotrexate (≥15 mg/week), CPM: cyclophosphamide (750 mg intravenous (i.v.) pulses for ≥3 months): MMF: mycophenolate mofetil (≥2 g/d); n.a.: not applicable; (British Isles Lupus Assessment (BILAG) was used only for SLE patients; relapses were documented only if patient achieved remission after B-cell depletion therapy (BCDT)); dsDNA: double-stranded DNA.